甲磺酸伊马替尼用于慢性粒细胞白血病的临床疗效及对患者的抑郁、焦虑评分影响
Clinical efficacy of imatinib mesylate in chronic myeloid leukemia and its influence on depression and anxiety scores
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2021, 48(5) |
| 作者 |
|
| 作者单位 |
许昌市中心医院血液内科 ;
|
| 摘要 |
[摘要]目的：探讨慢性粒细胞白血病患者选用甲磺酸伊马替尼治疗的价值。方法：纳入85例慢性粒细胞白血病患者研究（2017年1月~2020年12月），按随机数字表分为对照组（n=42，选用原研甲磺酸伊马替尼（格列卫）治疗）、观察组（n=43，选用国产甲磺酸伊马替尼（天晴），统计两组临床疗效、心理状态、免疫指标、预后效果。结果：（1）临床疗效：观察组（90.70%）与对照组（92.86%）相比无显著差异P>0.05。（2）心理状态：治疗前与治疗后两组组间SDS、SAS评分对比无差异；治疗前后两组组内对比无显著差异（P>0.05）。（3）免疫指标：观察组观察组CD3+（62.11±9.82%）、CD4+（45.72±8.34%）、CD4+/CD8+（1.92±0.52%）与对照组相比无统计差异，组间对比P>0.05。（4）预后效果：观察组2年生存率（93.02%）与对照组（92.86%）相比无显著差异P>0.05；不良反应率（11.63%）与对照组（9.52%）相比无显著差异P>0.05。结论：国产甲磺酸伊马替尼与原研达到同样疗效、安全性，且对患者焦虑、抑郁状态均无明显影响，值得借鉴。
|
| Abstract |
[Abstract] Objective: To explore the value of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods: 85 patients with chronic myeloid leukemia (January 2017 ~ December 2020) were randomly divided into control group (n = 42, treated with imatinib mesylate) and observation group (n = 43, treated with domestic imatinib mesylate (Tianqing). The clinical efficacy, psychological status, immune indexes and prognosis of the two groups were statistically analyzed. Results: (1) clinical efficacy: there was no significant difference between the observation group (90.70%) and the control group (92.86%), P > 0.05. (2) Psychological status: there was no difference in SDS and SAS scores between the two groups before and after treatment; There was no significant difference between the two groups before and after treatment (P > 0.05). (3) Immune indexes: observation group, observation group CD3 + (62. 11 1 ± 9.82%）、CD4+（45.72 ± 8.34%）、CD4+/CD8+（1.92 ± There was no statistical difference between the two groups (P > 0.05). (4) Prognosis: there was no significant difference in 2-year survival rate between the observation group (93.02%) and the control group (92.86%), P>0.05; There was no significant difference between the adverse reaction rate (11.63%) and the control group (9.52%), P > 0.05. Conclusion: Domestic imatinib mesylate has the same efficacy and safety as the original study, and has no significant effect on anxiety and depression of patients, which is worthy of reference.
|
| 关键词 |
关键词：甲磺酸伊马替尼；慢性粒细胞白血病；临床疗效；抑郁；焦虑评分；免疫功能
|
| KeyWord |
Keywords: imatinib mesylate; Chronic myeloid leukemia; Clinical effect; Depression; Anxiety score; immunity
|
| 基金项目 |
|
| 页码 |
905-908 |
梅书豪*.
甲磺酸伊马替尼用于慢性粒细胞白血病的临床疗效及对患者的抑郁、焦虑评分影响 [J].
国际精神病学杂志.
2021; 48; (5).
905 - 908.